Heart Failure With Reduced Ejection Fraction

WASHINGTON — In patients with moderate aortic stenosis and HF with reduced ejection fraction, transcatheter aortic valve replacement did not improve clinical outcomes but may raise quality of life vs. clinical surveillance, data show.

Baroreflex activation therapy plus optimal medical therapy improved quality of life at 2 years in patients with HF with reduced ejection fraction compared with optimal medical therapy alone, researchers reported.

In patients with atrial fibrillation and heart failure with reduced ejection fraction, cryoballoon ablation was noninferior to radiofrequency ablation, according to the results of the CRABL-HF trial.

Twelve circulating proteins associated with obesity and heart failure may inform treatment for adults with both conditions, according to a study published in Obesity.

Bayer announced positive top-line results for the FINEARTS-HF trial of finerenone, in which the drug reduced risk for cardiovascular death and heart failure events in patients with HF with preserved or mildly reduced ejection fraction.

HF is associated with a fourfold increased risk for death and a sixfold to ninefold increased risk for sudden cardiac death, and its direct and indirect costs are estimated to reach $69.8 billion annually in the United States by 2030.

Renin-angiotensin system blockade conferred similar mortality benefits for Black vs. non-Black patients with HF, and despite less benefit for hospitalization for Black patients, absolute benefit was comparable, researchers reported.

ATLANTA — A phone-based telehealth model improved rates of guideline-directed classes of HF drugs filled at the pharmacy at 30 days among adults with HF with reduced ejection fraction in Navajo Nation, where access to care is limited.

ATLANTA — Transcatheter implant of an inter-atrial shunt had drastically different results depending on ejection fraction in patients with HF, a speaker reported at the American College of Cardiology Scientific Session.

An autologous cell therapy was safe for patients with heart failure with reduced ejection fraction and showed a signal of benefit for patients with elevated baseline N-terminal pro-B-type natriuretic peptide, researchers reported.